![]() ![]() While no studies to date have examined PAP for caregiver distress, this article provides a rationale for investigating PAP as a potential novel treatment for this indication. In recent years, clinical trials have demonstrated that psychedelic-assisted psychotherapy (PAP) may have applications for treating a range of medical and psychiatric conditions that have significant overlap in symptoms to those seen in caregiver distress. Although evidence-based treatments for care-giver distress exist, they do not sufficiently address all its components. Caregiver distress is highly prevalent, affecting an estimated 30-70% of individuals across various caregiver populations. Caregiver distress refers to a constellation of physiological, psychological, interpersonal, and spiritual impairments that typically result when an individual's own health becomes affected while caring for another. Providing care to a sick loved one can contribute to personal growth but can also cause significant strain. In particular, developmental considerations for assessing both therapist and patient applicability in utilizing this modality are proposed.īackground: More than 50 million people in the United States serve as uncompensated informal caregivers to chronically ill friends or family members. The paper concludes with a discussion of practical and philosophical considerations germane to the safe and ethical application of psychedelics in healthcare. These sections are then integrated in a theoretical rationale for psychedelic-assisted mystical states as a means of facilitating the development of self-transcendence and, through it, the remediation of existential suffering. This is followed with a conceptual overview of existential suffering at the end-of-life and the process of self-transcendence. It begins with an overview of the classic psychedelics and their application in psychotherapy, highlighting recent studies. As such, this article seeks to advance the rationale for the use of psychedelic substances in the provision of psychedelic-assisted psychotherapy for patients nearing the end-of-life. ![]() However, both historic and recent studies of psychedelic-assisted psychotherapy have reported marked alleviation of this suffering. MAPS' harm-reduction efforts are intended to avoid backlash and build a post-prohibition world by assisting non-medical users to transform difficult psychedelic experiences into opportunities for growth.Īlthough existential suffering is amongst the most devastating forms of distress experienced by many patients nearing the end-of-life, it is often unsatisfactorily addressed due to a paucity of effective interventions. MAPS meets the challenges of drug development through a clinical research team led by a former Novartis drug development professional experienced in the conduct, monitoring, and analysis of clinical trials. MAPS' program of research expanded to include a trial of lysergic acid diethylamide (LSD)-assisted psychotherapy for anxiety when facing life-threatening illness, observational studies of ibogaine in the treatment of addiction, and studies of MDMA for social anxiety in people with autism spectrum disorders. Overcoming many hurdles, MAPS developed the first double-blind, placebo-controlled trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) and plans for FDA prescription approval in 2021. MAPS was created as a non-profit psychedelic pharmaceutical company in response to the 1985 scheduling of 3,4-methylenedioxymethamphetamine (MDMA). The article traces the trajectory of MAPS from inception in 1986 to its present, noting future goals with respect to research, outreach, and harm reduction. ![]() ![]() This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future would be aided by the therapeutic and spiritual potential of psychedelic substances. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |